News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|June 19, 2024

Exploring Changes in Atopic Dermatitis Severity Across the Pregnancy Journey

Author(s)Elizabeth Kiracofe, MD, FAAD, Jenny Murase, MD, FAAD

Jenny Murase, MD, describes how rising estrogen levels cause a shift in immune response from Th1 to Th2, causing potential atopic dermatitis exacerbations for patients who are pregnant.

Episodes in this series

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 1 Unveiling Treatment Gaps: Expert Perspectives on the Undermanagement of Patients with Atopic Dermatitis and Childbearing Potential

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 2 Fostering Communication: Promoting Dialogue on Atopic Dermatitis Treatment Concerns in Patients of Childbearing Potential

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 3 Exploring Changes in Atopic Dermatitis Severity Across the Pregnancy Journey

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 4 Navigating Treatment Choices: Balancing Treatment Options for Childbearing-Age Patients

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 5 Insights on Transcription Binding in Atopic Dermatitis

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 6 Informed Decisions: Dialogue with Treatment-Naïve Pregnant Patients Regarding Systemic Atopic Dermatitis Treatment Options

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 7 Managing Atopic Dermatitis Treatment Escalation in Pregnancy: Considerations and Approaches

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 8 Urgent Need for Consensus on Systemic Treatments for Atopic Dermatitis in Childbearing-Age Populations

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 9 Considerations for Breastfeeding, Lactation, and Postpartum in Family Planning Patients with Atopic Dermatitis

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 10 Concluding Remarks: Systemic Treatment Considerations for Atopic Dermatitis in Patients of Childbearing Potential

EP. 11 Ten Clinical Considerations to Manage AD in Pregnant Patients

EP. 11 Ten Clinical Considerations to Manage AD in Pregnant Patients

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC

Phase 2 Nemolizumab Trial Opens for CPUO

First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA

Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1

© 2025 MJH Life Sciences^®

All rights reserved.